Figure 1.

Current treatment options in advanced NSCLC according to molecular gene testing. Novel generations of TKIs, where available, were initially positioned in a therapeutic sequence, but they are established as front-line treatments across driver mutations. Drug classes: Tyrosine kinase inhibitors: Osimertinib, gefitinib, erlotinib, afatinib, dacomitinib, mobocertinib, alectinib, brigatinib, lorlatinib, ceritinib, crizotinib, entrectinib, selpercatinib, pralsetinib, capmatinib, tepotinib, larotrectinib|small molecule inhibitors: dabrafenib, trametinib, sotorasib, adagrasib|bispecific antibodies: amivantamab|Antibody-drug conjugates: trastuzumab-deruxtecan|Abbreviations: CT = chemotherapy; Atezo = atezolizumab; Pembro = pembrolizumab; Nivo = nivolumab|Ipi = ipilimumab|beva = bevacizumab.